onjunctival melanoma (CM) is a rare but potentially deadly ocular malignant condition, with a 10-year disease-specific mortality of 9% to 35%. 1 Primary treatment of CM consists of local surgical excision with wide margins and adjuvant therapy (cryotherapy, brachytherapy, and/or topical application of mitomycin C). However, regional and systemic metastasis occurs in approximately 30% of patients within 3 years, and there are no effective treatments for metastatic disease. 1 Conjunctival melanoma appears to be a distinct entity compared with other mucosal melanomas. In contrast to these malignant conditions, CM incidence is often associated with UV sunlight exposure. Conjunctival melanoma is also associated with a higher 5-year survival rate (86%) compared with melanomas of the gastrointestinal tract (4%-33%), urogenital tract (7%-22%), and respiratory mucosal tissues (0%-31%); this difference is possibly related to earlier detection or differences in the innate aggressiveness of the tumor. 2 The molecular attributes of CM remain poorly characterized, which is a problem that has hindered the development of novel therapies. One study 3 reported mutations in BRAF and NRAS in 29% and 18% of CMs, respectively, but the technology used in this study did not allow for a comprehensive assessment of driver mutations, chromosome copy number aberrations (CNAs), and mutational signatures. In the present study, whole-exome sequencing (WES) permits more comprehensive characterization of the molecular biology of CM.
MethodsFive formalin-fixed, paraffin-embedded, archival CM specimens were selected based on the availability of sufficient tissue for testing. Tumor DNA was extracted from all 5 and prepared for WES. Ethical approval was obtained from the University of Miami institutional review board for this study, IMPORTANCE Conjunctival melanoma (CM) is a highly aggressive ocular cancer for which treatment options are limited; the molecular pathogenesis is poorly understood. OBJECTIVE To identify the molecular characteristics of CM using next-generation whole-exome sequencing (WES).DESIGN, SETTING, AND PARTICIPANTS Whole-exome sequencing was performed on tumor DNA extracted from the archived specimens of 5 patients with CM who had been treated with surgical excision between 2006 and 2011. These samples were analyzed at a tertiary academic ocular oncology referral center using a customized bioinformatic pipeline.MAIN OUTCOMES AND MEASURES Sample analyses were designed to detect driver mutations, chromosome copy number aberrations, and mutation signatures.
RESULTSThe study's 5 patients ranged in age from 51 to 77 years. Four of the 5 were female, and all were white. Mutations were detected in known oncogenes, including BRAF, NRAS, NF1, EGFR, ALK, TERT, and APC. None of the mutations associated with uveal melanoma were found. All samples demonstrated a C→T mutation signature typical of UV-induced DNA damage. The most common CNA was a gain in chromosome 6p.
CONCLUSIONS AND RELEVANCEIn these 5 patients, WES allowed identification of m...